Mumbai-based Entod Pharmaceuticals has announced that it has recently
inaugurated a new state-of-art research and development facility at Navi
Inaugurating the facility, the chairman of the group, Kishore Masurkar, said, “We dedicate this research facility to our founder, the late GV Masurkar on the occasion of his 100th birth anniversary year, whose passion for pharmaceutical research, therapeutic innovation & entrepreneurship made him into a pharmaceutical visionary & pioneer of his times.”
According to the company statement, the facility has been approved by the Department of Scientific and Industrial Research (DSIR). will allow the group to focus on ophthalmic, ENT, and dermatology formulation development, allowing the group to develop new products, formulations, and molecular research.
Pointing out that the R&D expansion will help in broadening its presence in the country while also acknowledging India’s specialised capabilities and potential, the Chief Executive Officer, Nikkhil K Masurkar, said, “If Indian pharmaceutical businesses wish to advance in terms of value, they should concentrate on how to deepen their R&D and inventions.”
“With the G20 presidency, India has an opportunity to set the global agenda and promote inclusive and sustainable industrialisation and foster innovation. In particular, we feel that India's G20 Presidency will encourage innovation and substantially increase the numbers of researchers as well as public and private spending on R&D,” he added.